Dexamethasone pretreatment reduces GI complications in DLBCL patients with GI involvement without compromising efficacy. The study showed no significant differences in response rates or survival ...
R-CHOP is a combination of five drugs that work together to target and kill cancer cells. It’s a first-line treatment for aggressive non-Hodgkin’s lymphoma, a group of blood cancers. Most often, ...
Although ibrutinib adds to the cost of treatment, its benefits over the long term justify the cost, investigators found. Adding ibrutinib (Imbruvica) to the R-CHOP regimen (rituximab, cyclophosphamide ...
Selection bias is one of the most common issues in designing trials. This is illustrated in the PYRAMID trial, which showed a 2-year PFS of 78% for patients with non-GCB DLBCL compared with a 2-year ...
The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A randomized phase 2 study of CDX-1127 (varlilumab) in combination with nivolumab in patients with relapsed or refractory aggressive ...
The combination of Epkinly and R-mini-CHOP showed a 93% ORR and 86% CR rate in elderly DLBCL patients. At two years, 79% of patients remained in complete response, with a 76% progression-free survival ...
Please provide your email address to receive an email when new articles are posted on . The regimen conferred a 71% complete response rate among older adults with newly diagnosed DLBCL. Median PFS and ...
The replacement of vincristine with Velcade (bortezomib) in the R-CHOP regimen for the treatment of transplantation-ineligible patients with newly diagnosed mantle cell lymphoma improved overall ...
Please provide your email address to receive an email when new articles are posted on . CHICAGO — Epcoritamab plus R-CHOP induced high complete metabolic response rates in previously untreated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results